Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Shattuck Labs, Inc. (STTK : NSDQ)

• Company Description    Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North Carolina and Austin, Texas. Shattuck Labs Inc. is based in Austin, United States. Number of Employees: 40

• Price / Volume Information    Yesterday's Closing Price: $6.10 Daily Weekly Monthly 20 Day Moving Average: 573,273 shares Shares Outstanding: 76.68 (millions) Market Capitalization: $467.75 (millions) Beta: 1.18 52 Week High: $8.33 52 Week Low: $0.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.26% -24.16% 12 Week 50.99% 39.58% Year To Date 67.12% 53.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 W. 5TH STREET SUITE 1200 - AUSTIN,TX 78701 USA ph: 512-900-4690 fax: - investorrelations@shattucklabs.com http://www.shattucklabs.com

• General Corporate Information    Officers Taylor Schreiber - Chief Executive Officer and Director George Golumbeski - Chairman Andrew R. Neill - Chief Financial Officer Helen M. Boudreau - Director Neil Gibson - Director Peer Information Shattuck Labs, Inc. (CORR.) Shattuck Labs, Inc. (RSPI) Shattuck Labs, Inc. (CGXP) Shattuck Labs, Inc. (BGEN) Shattuck Labs, Inc. (GTBP) Shattuck Labs, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 82024L103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 76.68 Most Recent Split Date: (:1) Beta: 1.18 Market Capitalization: $467.75 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.51 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.88 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 51.85% vs. Previous Quarter: -8.33% Sales Growth vs. Year Ago Period: -66.63% vs. Previous Quarter: -% ROE 03/31/26 - -60.73 12/31/25 - -65.03 09/30/25 - -73.82 ROA 03/31/26 - -55.75 12/31/25 - -58.65 09/30/25 - -65.96 Current Ratio 03/31/26 - 22.07 12/31/25 - 11.69 09/30/25 - 17.00 Quick Ratio 03/31/26 - 22.06 12/31/25 - 11.70 09/30/25 - 17.00 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -4,987.40 12/31/25 - -4,880.90 09/30/25 - -5,489.50 Book Value 03/31/26 - 1.25 12/31/25 - 1.30 09/30/25 - 1.47 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©